Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Biodelivery Sciences International Inc's Business Segments
Biodelivery Sciences International Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Annual Results
Revenue by Product & Service Category -
- Product98.7%
- Belbuca88.9%
- Symproic9.8%
- Royalty1.3%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 165 | 98.7% |
| Belbuca | $ 148 | 88.9% |
| Symproic | $ 16 | 9.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Biodelivery Sciences International Inc dataset.
Description of Biodelivery Sciences International Inc
Biodelivery Sciences International Inc (BDSI) is a pharmaceutical company based in Raleigh, North Carolina, focused on developing and commercializing innovative treatments for chronic pain, addiction, and other central nervous system disorders using its proprietary delivery technologies.
The company was founded in 1997 as BioDelivery Technologies Inc. and changed its name to BDSI in 2009. Its core technologies include BioErodible MucoAdhesive (BEMA) and Bioral platforms, which are designed to improve the delivery of drugs into the bloodstream through oral and transmucosal routes, respectively.
BDSI's current commercialized products include Belbuca (buprenorphine buccal film), which is used for chronic pain management, and Bunavail (buprenorphine and naloxone buccal film), which is used for medication-assisted treatment of opioid addiction. The company also has a pipeline of products in various stages of development, including Clonidine Topical Gel for diabetic neuropathy and a long-acting version of buprenorphine for chronic pain management.
In addition to its proprietary technologies, BDSI also has established partnerships with several pharmaceutical companies, including Endo Pharmaceuticals and Meda Pharmaceuticals, to develop and commercialize new products.
BDSI's management team includes experienced professionals with backgrounds in pharmaceuticals, business, and finance. The company is committed to innovation and improving patient care, and its technologies and products have received recognition from healthcare professionals and patients alike.
The company was founded in 1997 as BioDelivery Technologies Inc. and changed its name to BDSI in 2009. Its core technologies include BioErodible MucoAdhesive (BEMA) and Bioral platforms, which are designed to improve the delivery of drugs into the bloodstream through oral and transmucosal routes, respectively.
BDSI's current commercialized products include Belbuca (buprenorphine buccal film), which is used for chronic pain management, and Bunavail (buprenorphine and naloxone buccal film), which is used for medication-assisted treatment of opioid addiction. The company also has a pipeline of products in various stages of development, including Clonidine Topical Gel for diabetic neuropathy and a long-acting version of buprenorphine for chronic pain management.
In addition to its proprietary technologies, BDSI also has established partnerships with several pharmaceutical companies, including Endo Pharmaceuticals and Meda Pharmaceuticals, to develop and commercialize new products.
BDSI's management team includes experienced professionals with backgrounds in pharmaceuticals, business, and finance. The company is committed to innovation and improving patient care, and its technologies and products have received recognition from healthcare professionals and patients alike.
Biodelivery Sciences International, Inc. (BDSI) is a dynamic specialty pharmaceutical company that focuses on creating and marketing innovative solutions for pain management and addiction treatment. With an emphasis on oral formulations, BDSI utilizes its proprietary Biorale drug delivery technology to effectively target the central nervous system, facilitating the delivery of therapeutic agents for a variety of medical conditions. Below is an extensive overview of BDSIs key segments, products, and services.
1. Pain Management Products
BDSI develops a robust lineup of products aimed at alleviating acute and chronic pain. The primary offerings in this segment include:
- BELBUCA® (buprenorphine HCl) Buccal Film: This product is designed specifically for managing moderate to severe pain. BELBUCA® utilizes buprenorphine, a partial opioid agonist, delivered via a buccal film that adheres to the inside of the cheek. This formulation allows for controlled release and absorption through the oral mucosa, providing a convenient and effective option for patients seeking relief from persistent pain. Its unique delivery system allows for a lower dose of opioid while managing pain effectively, potentially reducing the risk of side effects often associated with higher doses.
- SYNDROS® (dronabinol oral solution): SYNDROS® provides a synthetic formulation of delta-9-THC, the primary psychoactive component of cannabis. This oral solution is indicated for two primary conditions: anorexia associated with significant weight loss in patients with AIDS, and nausea and vomiting linked to chemotherapy. The formulation allows for reliable dosing and ease of administration, ensuring patients can manage their symptoms effectively and with greater precision.
Opioid Addiction Treatment Products
Addressing the opioid crisis, BDSI has developed targeted products for the treatment of opioid addiction:
- BUNAVAIL® (buprenorphine and naloxone) Buccal Film: BUNAVAIL® combines buprenorphine, an opioid agonist, with naloxone, an opioid antagonist, to provide an effective maintenance therapy for individuals with opioid dependence. The buccal film delivery system enhances bioavailability and user convenience, empowering patients with a practical solution while simultaneously reducing the potential for misuse associated with traditional oral forms of buprenorphine alone.
Contract Development and Manufacturing Services
BDSI extends its expertise beyond its proprietary products by offering comprehensive contract development and manufacturing services. These services include:
- Formulation Development: BDSI assists clients in developing tailored pharmaceutical formulations, leveraging its advanced knowledge and technological capabilities to create effective delivery systems for a variety of drugs.
- Analytical Method Development and Validation: The company provides rigorous analytical support to ensure the quality and consistency of pharmaceutical products, including method development and validation services that comply with regulatory standards.
- Good Manufacturing Practices (GMP) Manufacturing: BDSI operates under GMP guidelines to manufacture products that meet stringent quality and safety requirements. This positions BDSI as a reliable partner for clients looking for high-quality product development and manufacturing solutions.
Research and Development
BDSI is dedicated to pushing the boundaries of drug delivery innovation through ongoing research and development efforts. Key aspects of its R&D focus include:
- New Drug Discovery: BDSI invests in identifying and developing new therapeutic candidates that address unmet medical needs, particularly in pain management and addiction treatment.
- Enhancing Existing Products: The company continually seeks to improve its existing product portfolio by optimizing formulations and delivery methods, thus enhancing efficacy and patient compliance.
- Collaborative Innovation: BDSI actively collaborates with academic institutions and industry partners to foster innovation. This collaborative approach facilitates the sharing of knowledge and resources, driving advancements that can lead to improved patient outcomes.
Conclusion
Biodelivery Sciences International, Inc. stands out in the pharmaceutical landscape with its commitment to developing innovative drug delivery systems tailored for pain management and addiction treatment. With a strong product portfolio, comprehensive manufacturing services, and a focus on research and development, BDSI is well-positioned as a key player in enhancing therapeutic options for patients and contributing to the fight against opioid dependence.
1. Pain Management Products
BDSI develops a robust lineup of products aimed at alleviating acute and chronic pain. The primary offerings in this segment include:
- BELBUCA® (buprenorphine HCl) Buccal Film: This product is designed specifically for managing moderate to severe pain. BELBUCA® utilizes buprenorphine, a partial opioid agonist, delivered via a buccal film that adheres to the inside of the cheek. This formulation allows for controlled release and absorption through the oral mucosa, providing a convenient and effective option for patients seeking relief from persistent pain. Its unique delivery system allows for a lower dose of opioid while managing pain effectively, potentially reducing the risk of side effects often associated with higher doses.
- SYNDROS® (dronabinol oral solution): SYNDROS® provides a synthetic formulation of delta-9-THC, the primary psychoactive component of cannabis. This oral solution is indicated for two primary conditions: anorexia associated with significant weight loss in patients with AIDS, and nausea and vomiting linked to chemotherapy. The formulation allows for reliable dosing and ease of administration, ensuring patients can manage their symptoms effectively and with greater precision.
Opioid Addiction Treatment Products
Addressing the opioid crisis, BDSI has developed targeted products for the treatment of opioid addiction:
- BUNAVAIL® (buprenorphine and naloxone) Buccal Film: BUNAVAIL® combines buprenorphine, an opioid agonist, with naloxone, an opioid antagonist, to provide an effective maintenance therapy for individuals with opioid dependence. The buccal film delivery system enhances bioavailability and user convenience, empowering patients with a practical solution while simultaneously reducing the potential for misuse associated with traditional oral forms of buprenorphine alone.
Contract Development and Manufacturing Services
BDSI extends its expertise beyond its proprietary products by offering comprehensive contract development and manufacturing services. These services include:
- Formulation Development: BDSI assists clients in developing tailored pharmaceutical formulations, leveraging its advanced knowledge and technological capabilities to create effective delivery systems for a variety of drugs.
- Analytical Method Development and Validation: The company provides rigorous analytical support to ensure the quality and consistency of pharmaceutical products, including method development and validation services that comply with regulatory standards.
- Good Manufacturing Practices (GMP) Manufacturing: BDSI operates under GMP guidelines to manufacture products that meet stringent quality and safety requirements. This positions BDSI as a reliable partner for clients looking for high-quality product development and manufacturing solutions.
Research and Development
BDSI is dedicated to pushing the boundaries of drug delivery innovation through ongoing research and development efforts. Key aspects of its R&D focus include:
- New Drug Discovery: BDSI invests in identifying and developing new therapeutic candidates that address unmet medical needs, particularly in pain management and addiction treatment.
- Enhancing Existing Products: The company continually seeks to improve its existing product portfolio by optimizing formulations and delivery methods, thus enhancing efficacy and patient compliance.
- Collaborative Innovation: BDSI actively collaborates with academic institutions and industry partners to foster innovation. This collaborative approach facilitates the sharing of knowledge and resources, driving advancements that can lead to improved patient outcomes.
Conclusion
Biodelivery Sciences International, Inc. stands out in the pharmaceutical landscape with its commitment to developing innovative drug delivery systems tailored for pain management and addiction treatment. With a strong product portfolio, comprehensive manufacturing services, and a focus on research and development, BDSI is well-positioned as a key player in enhancing therapeutic options for patients and contributing to the fight against opioid dependence.